ArticleWorld journal of gastroenterology2017
Suppression of colorectal tumorigenesis by recombinant
Article in World journal of gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- A systemic review of the role of enterotoxic Bacteroides fragilis in colorectal cancer.Neoplasia (New York, N.Y.) · 2022Pooled it
- Article
- Potential Pathogens Associated with Colorectal Cancer.Current pharmaceutical biotechnology · 2025Review
- Microbiota-derived metabolites in tumorigenesis: mechanistic insights and therapeutic implications.Frontiers in pharmacology · 2025Review
- Breaking resistance: in silico subtractive and comparative genomics approaches for drug targeting in Bacteroides fragilis.Biotechnology letters · 2024Article
- Intratumoral microorganisms in tumors of the digestive system.Cell communication and signaling : CCS · 2024Review
- Probiotics and postbiotics in colorectal cancer: Prevention and complementary therapy.World journal of gastroenterology · 2022Review
- Bacteria-Mediated Oncogenesis and the Underlying Molecular Intricacies: What We Know So Far.Frontiers in oncology · 2022Review
- Familial adenomatous polyposis and changes in the gut microbiota: New insights into colorectal cancer carcinogenesis.World journal of gastrointestinal oncology · 2021Review
- The Mechanism ofThe Malaysian journal of medical sciences : MJMS · 2020Review
- EnterotoxigenicInternational journal of medical sciences · 2020Article
- Colorectal cancer: The epigenetic role of microbiome.World journal of clinical cases · 2019Review
- The role of microbiota in the development of colorectal cancer.International journal of cancer · 2019Review
- Microbiome and colorectal cancer: Roles in carcinogenesis and clinical potential.Molecular aspects of medicine · 2019Review
- Toll-Like Receptor 2-Mediated Suppression of Colorectal Cancer Pathogenesis by Polysaccharide A FromFrontiers in microbiology · 2018Article
- Role of intestinal flora in colorectal cancer from the metabolite perspective: a systematic review.Cancer management and research · 2018Review
- The colibactin-producingGut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the impact of recombinant
methodsRecombinant proBFT-2 was expressed in
resultsRecombinant BFT-2 was successfully obtained, along with its biological activity. The most obvious weight loss occurred in the AD group compared with the ADLT group (21.82 ± 0.68
conclusionOral administration with lower-dose biologically active recombinant BFT-2 inhibited colorectal tumorigenesis in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.